TLSI
NASDAQ · Biotechnology
Trisalus Life Sciences Inc
$4.34
-0.27 (-5.86%)
Financial Highlights (FY 2026)
Revenue
67.64M
Net Income
-58,764,473
Gross Margin
84.6%
Profit Margin
-86.9%
Rev Growth
—
D/E Ratio
0.20
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 84.6% | 38.7% | 38.7% | 38.7% |
| Operating Margin | -59.7% | -6.4% | -7.4% | -7.4% |
| Profit Margin | -86.9% | -6.9% | -8.6% | -9.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 67.64M | 47.23M | 45.65M | 46.65M |
| Gross Profit | 57.20M | 18.30M | 17.68M | 18.07M |
| Operating Income | -40,366,300 | -3,022,090 | -3,373,799 | -3,460,559 |
| Net Income | -58,764,473 | -3,256,844 | -3,940,718 | -4,180,453 |
| Gross Margin | 84.6% | 38.7% | 38.7% | 38.7% |
| Operating Margin | -59.7% | -6.4% | -7.4% | -7.4% |
| Profit Margin | -86.9% | -6.9% | -8.6% | -9.0% |
| Rev Growth | — | +7.1% | +0.6% | -1.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 23.65M | 115.31M | 91.39M | 101.31M |
| Total Equity | 118.27M | 107.73M | 99.32M | 108.24M |
| D/E Ratio | 0.20 | 1.07 | 0.92 | 0.94 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -39,428,003 | -4,196,050 | -4,663,249 | -4,114,414 |
| Free Cash Flow | — | -5,024,799 | -4,621,021 | -5,351,943 |